Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39 results about "Pharmorubicin" patented technology

Tumor targeted lipidosome drug-delivering system, preparation method and application

The invention discloses a tumor targeted lipidosome drug-delivering system, a preparation method and an application. The system comprises a CRNGRGPDC polypeptide modified invisible lipidosome and an antitumor drug, wherein the invisible lipidosome comprises a) hydrogenated soyabean lecithin, b) cholesterol, c) polyethylene glycol-distearoyl phosphatidylethanolamine and d) distearoyl phosphatidylethanolamine-polyethylene glycol-CRNGRGPDC; the mole ratio of the components are as follows: a:b=(5-1):(1-5), a:c=1000:(0.1-100) and a:d=1000:(0.1-100); adriamycin amycin or pharmorubicin is taken as the antitumor drug; the weight percentage of the invisible lipidosome in the system is 75%-98%; the balance is the antitumor drug. The CRNGRGPDC provided by the invention is a cyclic peptide, is taken as aglucon and has pathoklisis with tumor cells. The invention also discloses the preparation method for the polypeptide modified lipidosome containing CRNGRGPDC sequence. The prepared polypeptide modified lipidosome containing CRNGRGPDC sequence is used for intravenous injection and is targeted to the tumor under the tumor EPR effect and CRNGRGPDC mediation. The lipidosome drug-delivering system can be used for targeting and delivering the drugs for tumor diagnosis or treatment.
Owner:EAST CHINA NORMAL UNIV

Tumor-targeted multi-purpose nanometer drug delivery system as well as preparation method and applications thereof

The invention discloses a tumor-targeted multi-purpose nanometer drug delivery system as well as a preparation method and applications of the tumor-targeted multi-purpose nanometer drug delivery system. The system comprises multi-purpose nanoparticles modified by tumor penetrating peptide RGERPPR and an anti-tumor medicine, wherein the multi-purpose nanoparticles adopt the T1-T2 dual-mode magnetic resonance contrast agent; the anti-tumor medicine is adriamycin or pharmorubicin; and the weight of the anti-tumor medicine accounts for 10-35 % in the system. The drug delivery system has the following features: the grain diameter is 60-200 nm, and the particles are spherical; the T1 contrast agent Gd-DTPA and the T2 contrast agent Fe3O4 are simultaneously utilized, and the highly accurate diagnosis information is provided; the water solubility and biocompatibility of the medicine are improved, and the curative effects and bioavailability of the medicine are improved; the drug delivery system can be used for intravenous injection, and targets to the tumor tissue by utilizing the RGERPPR mediation effect and the tumor EPR effect, and the system has the obvious inhibiting effect for the growth of the brain glioma tumor; and the drug delivery system can be used for realizing the tumor diagnosis and treatment integration.
Owner:EAST CHINA NORMAL UNIV

Anti-cancer composition loading both platinum compound and synergist

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH

Preparation of fatty acid-RGD-fatty alcohol conjugate mediated epirubicin targeted liposome and evaluation on anticancer activity

The invention discloses preparation of fatty acid-RGD-fatty alcohol conjugate mediated epirubicin targeted liposome and evaluation on anticancer activity. According to the invention, the conjugate has the following structural formula: CH3(CH2)nCO-Arg-Gly-Asp-OCH2(CH2)10CH3, wherein n is equal to 4-16. An anticancer medicine is introduced into the conjugate to obtain anticancer targeted liposome medicine; the liposome can increase the concentration of the anticancer medicine at a target position, reduce the toxic and side effects of the anticancer medicine at a non-target position, and improve the therapeutic index of the medicine.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Nanometer composite graphene hydrogel system used for breast cancer combined chemotherapy, and preparation method thereof

The invention discloses a preparation method of a nanometer composite graphene hydrogel system having pH / temperature dual response and simultaneously carrying breast cancer combined chemotherapy drugs comprising paclitaxel and epirubicin. The method comprises the following steps: 1, preparing hydrophobic drug paclitaxel supported graphene PTX@GX; 2, carrying out a free radical polymerization reaction through adopting the PTX@GX as an additive and selecting temperature-sensitive N-isopropylacrylamide NIPAM monomer as first network to prepare single network hydrogel, and carrying out ultraviolet irradiation by selecting pH-responsive acrylic acid AA monomer as a second network in order to synthesize composite graphene double network hydrogel with pH / temperature dual response; 3, loading a hydrophilic drug epirubicin EPI to obtain a PTX and EPI dual supported nanometer composite graphene hydrogel double drug-loading system EPI@PTX@GDL; and 4, detecting the cytotoxicity by using the prepared drug-loading system through an MTM technology, and observing the form of living cells by using a fluorescence microscope. The invention also discloses an application of the prepared composite drug loading system in breast cancer therapy.
Owner:JINLING INST OF TECH

Anti-cancer composition loading both mtrosourea medicament and synergist

Disclosed is a slow release injection agent of anticancer composition containing nitrosourea drugs and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the nitrosourea drugs are selected from Carmustine, Nimustine or Fotemustine, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or temozolomide and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH

Preparation method of epirubicin and its intermediate

The invention provides a method for preparing epirubicin and an intermediate compatible with the method. The preparation method may include: reacting tert-butyldimethylsilyl chloride with N-trifluoroacetyl doxorubicin to obtain compound 1N-trifluoroacetyl-14-O-tert-butyldimethylsilyl doxorubicin Oxidation of compound 1 gives compound 24'-ketone-N-trifluoroacetyl-14-O-tert-butyldimethylsilyl doxorubicin; reduction of compound 2 gives compound 3N-trifluoroacetyl-14-O ‑tert-butyldimethylsilyl epirubicin; and subsequent deprotection and hydrolysis of compound 3 to obtain epirubicin. The method of the invention not only has low cost, few reaction steps, high yield and product purity, but also avoids serious pollution caused by bromination reaction in the traditional method.
Owner:ZHEJIANG HISUN PHARMA CO LTD

A kind of nanocomposite graphene hydrogel system for breast cancer combined chemotherapy and preparation method thereof

The invention discloses a preparation method of a nanometer composite graphene hydrogel system having pH / temperature dual response and simultaneously carrying breast cancer combined chemotherapy drugs comprising paclitaxel and epirubicin. The method comprises the following steps: 1, preparing hydrophobic drug paclitaxel supported graphene PTX@GX; 2, carrying out a free radical polymerization reaction through adopting the PTX@GX as an additive and selecting temperature-sensitive N-isopropylacrylamide NIPAM monomer as first network to prepare single network hydrogel, and carrying out ultraviolet irradiation by selecting pH-responsive acrylic acid AA monomer as a second network in order to synthesize composite graphene double network hydrogel with pH / temperature dual response; 3, loading a hydrophilic drug epirubicin EPI to obtain a PTX and EPI dual supported nanometer composite graphene hydrogel double drug-loading system EPI@PTX@GDL; and 4, detecting the cytotoxicity by using the prepared drug-loading system through an MTM technology, and observing the form of living cells by using a fluorescence microscope. The invention also discloses an application of the prepared composite drug loading system in breast cancer therapy.
Owner:JINLING INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products